{"title":"他汀类药物对冠心病患者血清sCD40、sCD146及pap - an的影响","authors":"Huawen Li, Xia Zhou, Wenyan Zhu, Jing Zhang","doi":"10.5937/jomb0-55833","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To analyse the effects of statins on the levels of sCD40, sCD146 and PAPP-An in patients with coronary heart disease (CHD).</p><p><strong>Methods: </strong>126 patients with CHD treated from September 2022 to September 2024 were divided into a study group (n = 84) and a control group (n=42). The study group was randomly divided into groups A (n=42) and B (n=42). Patients in the control group were routinely treated with vasodilator, furosemide, digitalis and other cardiotonic agents. Based on routine treatment, patients in the study group were treated with Atto vastatin calcium tablets in group An and rosuvastatin calcium tablets in group B. Both groups were treated with 20 mg, oral administration before bedtime, and the treatment cycle was 3 months. The cardiac function grade, blood lipid level, serum sCD40, sCD146 and PAPP-A levels and adverse reactions were compared before and after treatment.</p><p><strong>Results: </strong>After treatment, the cardiac function of the three groups improved compared with that before treatment. The effect of patients in groups A and B was better than the control group. The blood lipid levels of the three groups were improved after treatment. The blood lipid levels of groups A and B were better than in the control group. The serum sCD40, sCD146, and PAPP-A levels between groups A and B were no different; after treatment, these in groups A and B were better than those in the control group. After treatment, there were some adverse reactions in all the three groups.</p><p><strong>Conclusions: </strong>Statins effectively treat sCD40, sCD146, and PAPP-An in patients with CHD. They can significantly improve their cardiac function and blood lipid levels and effectively regulate sCD40, sCD146, and PAPP-An levels in patients with coronary heart disease.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1003-1008"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433293/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of statins on serum sCD40, sCD146 and PAPP-An in patients with coronary heart disease.\",\"authors\":\"Huawen Li, Xia Zhou, Wenyan Zhu, Jing Zhang\",\"doi\":\"10.5937/jomb0-55833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To analyse the effects of statins on the levels of sCD40, sCD146 and PAPP-An in patients with coronary heart disease (CHD).</p><p><strong>Methods: </strong>126 patients with CHD treated from September 2022 to September 2024 were divided into a study group (n = 84) and a control group (n=42). The study group was randomly divided into groups A (n=42) and B (n=42). Patients in the control group were routinely treated with vasodilator, furosemide, digitalis and other cardiotonic agents. Based on routine treatment, patients in the study group were treated with Atto vastatin calcium tablets in group An and rosuvastatin calcium tablets in group B. Both groups were treated with 20 mg, oral administration before bedtime, and the treatment cycle was 3 months. The cardiac function grade, blood lipid level, serum sCD40, sCD146 and PAPP-A levels and adverse reactions were compared before and after treatment.</p><p><strong>Results: </strong>After treatment, the cardiac function of the three groups improved compared with that before treatment. The effect of patients in groups A and B was better than the control group. The blood lipid levels of the three groups were improved after treatment. The blood lipid levels of groups A and B were better than in the control group. The serum sCD40, sCD146, and PAPP-A levels between groups A and B were no different; after treatment, these in groups A and B were better than those in the control group. After treatment, there were some adverse reactions in all the three groups.</p><p><strong>Conclusions: </strong>Statins effectively treat sCD40, sCD146, and PAPP-An in patients with CHD. They can significantly improve their cardiac function and blood lipid levels and effectively regulate sCD40, sCD146, and PAPP-An levels in patients with coronary heart disease.</p>\",\"PeriodicalId\":16175,\"journal\":{\"name\":\"Journal of Medical Biochemistry\",\"volume\":\"44 5\",\"pages\":\"1003-1008\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433293/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5937/jomb0-55833\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-55833","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Effects of statins on serum sCD40, sCD146 and PAPP-An in patients with coronary heart disease.
Background: To analyse the effects of statins on the levels of sCD40, sCD146 and PAPP-An in patients with coronary heart disease (CHD).
Methods: 126 patients with CHD treated from September 2022 to September 2024 were divided into a study group (n = 84) and a control group (n=42). The study group was randomly divided into groups A (n=42) and B (n=42). Patients in the control group were routinely treated with vasodilator, furosemide, digitalis and other cardiotonic agents. Based on routine treatment, patients in the study group were treated with Atto vastatin calcium tablets in group An and rosuvastatin calcium tablets in group B. Both groups were treated with 20 mg, oral administration before bedtime, and the treatment cycle was 3 months. The cardiac function grade, blood lipid level, serum sCD40, sCD146 and PAPP-A levels and adverse reactions were compared before and after treatment.
Results: After treatment, the cardiac function of the three groups improved compared with that before treatment. The effect of patients in groups A and B was better than the control group. The blood lipid levels of the three groups were improved after treatment. The blood lipid levels of groups A and B were better than in the control group. The serum sCD40, sCD146, and PAPP-A levels between groups A and B were no different; after treatment, these in groups A and B were better than those in the control group. After treatment, there were some adverse reactions in all the three groups.
Conclusions: Statins effectively treat sCD40, sCD146, and PAPP-An in patients with CHD. They can significantly improve their cardiac function and blood lipid levels and effectively regulate sCD40, sCD146, and PAPP-An levels in patients with coronary heart disease.
期刊介绍：
The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly.
The Journal publishes original scientific and specialized articles on all aspects of
clinical and medical biochemistry,
molecular medicine,
clinical hematology and coagulation,
clinical immunology and autoimmunity,
clinical microbiology,
virology,
clinical genomics and molecular biology,
genetic epidemiology,
drug measurement,
evaluation of diagnostic markers,
new reagents and laboratory equipment,
reference materials and methods,
reference values,
laboratory organization,
automation,
quality control,
clinical metrology,
all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
